Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00603889 · ClinicalTrials.gov registry record · NA

Development of a Skin Test for the Na-ASP-2 Hookworm Antigen

A NA study, sponsored by Albert B. Sabin Vaccine Institute.

Completed
Registry status
NA
Development phase
12
Enrollment target

NCT00603889 is a NA study that has completed, run by Albert B. Sabin Vaccine Institute. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00603889, a NA study, has completed, sponsored by Albert B. Sabin Vaccine Institute.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target

Study Summary

Na-ASP-2 is a protein expressed during the larval stage of the N. americanus hookworm life cycle. In a clinical study in previously hookworm-infected adults in Brazil, this protein induced urticarial reactions (rash) in a subset of volunteers. This study will evaluate solutions of varying concentrations of the protein in both a skin prick-puncture and intradermal test that will eventually be used to screen volunteers living in hookworm endemic areas who are being considered as potential participants in vaccine trials, to reduce the potential of inducing allergic reactions in those vaccinated with the Na-ASP-2 Hookworm Vaccine.

Interventions

  • BIOLOGICAL Na-ASP-2 Skin Test Reagent

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2008-03
Est. Completion 2008-05
Phase NA

What the Registry Record Tells You About NCT00603889

The ClinicalTrials.gov registry entry for NCT00603889 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert B. Sabin Vaccine Institute, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Na-ASP-2 Skin Test Reagent is the first listed.

NCT00603889 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00603889 about?

NCT00603889 is a clinical study titled "Development of a Skin Test for the Na-ASP-2 Hookworm Antigen". Na-ASP-2 is a protein expressed during the larval stage of the N. americanus hookworm life cycle. In a clinical study in previously hookworm-infected adults in Brazil, this protein induced urticarial reactions (rash) in a subset of volunteers. This study will evaluate solutions of varying concentrat...

What is the current status of trial NCT00603889?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2008-03. Estimated completion is 2008-05.

What interventions are being tested in trial NCT00603889?

The interventions under investigation include: Na-ASP-2 Skin Test Reagent (BIOLOGICAL).

Who is sponsoring clinical trial NCT00603889?

This trial is sponsored by Albert B. Sabin Vaccine Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.